Investor Alert

New York Markets Close in:

Market Pulse Archives

Jan. 26, 2022, 8:06 a.m. EST

Abbott sold $2.3 billion in COVID-19 tests in the fourth quarter

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Abbott Laboratories (ABT)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Abbott Laboratories /zigman2/quotes/203724446/composite ABT -0.49% were down 0.8% in premarket trading on Wednesday. The company beat expectations for both earnings and revenue in the fourth quarter, bolstered by more than $2 billion in sales of its COVID-19 tests during the quarter's omicron surge. Abbott had earnings of $1.9 billion, or $1.11 per share, in the fourth quarter of 2021, compared with earnings of $2.1 billion, or $1.20 per share, in the same quarter in 2020. Adjusted earnings per share were $1.32, which is higher than the FactSet consensus of $1.21. Abbott reported revenue of $11.4 billion for the fourth quarter of 2021, up from the $10.7 billion in reported in the final quarter of 2020. The FactSet consensus was $10.7 billion. This was driven in part by $4.4 billion in sales in its diagnostics business, including the $2.3 billion that came from sales of its COVID-19 tests during the final three months of the year. The company said it expects to generate $2.5 billion in sales of COVID-19 tests in 2022, with those sales likely happening early in the year. It also said it expects adjusted EPS of $4.70 in 2022. "We see our guidance as a prudent starting point, given the unpredictability of the virus and variants," a spokesperson said in an email. Abbott's stock is down 12.4% so far this year; the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.38% has declined 8.6%.

$ 103.69
-0.51 -0.49%
Volume: 1.24M
June 5, 2023 1:10p
P/E Ratio
Dividend Yield
Market Cap
$181.20 billion
Rev. per Employee
+16.08 +0.38%
Volume: 0.00
June 5, 2023 1:10p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.